💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Global Health Limited (Medanta) is an India-based multi-specialty tertiary care provider in the North and East regions of India. Medanta delivers advanced, end-to-end healthcare in Delhi, Gurugram, Indore, Ranchi, Patna, and Lucknow through its network of approximately five…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, fairly priced.
Global Health is scored on the pharma / healthcare framework. It keeps a healthy 12.3% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.29× reported profit. Free cash flow is worth about -1.0% of its market value.
Over the last 3 years revenue compounded at 18%/yr and profit at 19%/yr. Book value itself has compounded 18%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 14.3%. In the latest quarter profit grew 11% versus the prior quarter.
At 67× earnings, the stock sits at the 58th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price already implies ~24%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 60.84 | 75.62 | better |
| P/B | 8.63 | 3.49 | worse |
| EV/EBITDA | 31.48 | 19.95 | worse |
| ROE | 14.3 | — | — |
| ROCE | 16.02 | 10.81 | better |
| ROA | 9.28 | 3.84 | better |
| Quick Ratio | 2.54 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 18% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
Net profit has risen every year — the hallmark of a compounder.
Operating margins have been stable around 16% — no major structural shift.
ROE at 14% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. 18% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.3× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 11% sequentially — momentum is building. Run-rate stepping up — recent quarters average 12% above earlier ones.
Profit jumped 11% QoQ — check if this is operating leverage or a one-off item. Quarterly margins are compressing (14% → 12%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 33.0% — dispersed ownership; institutional flows drive the stock. MF holding up 2.9pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.